| Project/Area Number |
20591848
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Hirosaki University |
|---|
Principal Investigator |
MORI Kazuyuki 弘前大学, 大学院・医学研究科, 助教 (40266903)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
OHYAMA Chikara 弘前大学, 大学院・医学研究科, 教授 (80282135)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
YANO Ikuya 日本ビーシージー製造株式会社, 研究開発顧問 (60047008)
|
|---|
| Project Period (FY) |
2008 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2010: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2009: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2008: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Keywords | BCG / ナノパーティクルBCG / 膀胱癌 / 直接効果 |
|---|
| Research Abstract |
Intravesical BCG therapy is effective treatment for non-muscle invasive bladder cancer, however, side effect is remaining. Nanoparticle BCG was prepared by disrupting live BCG and sized 42 to 500 nm. Nanoparticle BCG had identical direct antitumor effect as live BCG, but had a different mechanism, had direct antitumor effect against live BCG-resistant cell lines, and did not influence to normal cell line. These results suggested that nanoparticle BCG might reduce side effect, and might be used to develop new therapeutic drugs against live BCG-failure cases, invasive bladder cancer, or other tissue cancer.
|
